Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Vutrisiran: Pain in Extremity
Standard response letter on vutrisiran and the adverse event of pain in extremity.
Standard response letter on vutrisiran and the adverse event of pain in extremity.
Vutrisiran: Use in Patients with Wild-Type ATTR
Standard response letter on the use of vutrisiran in patients with wild-type ATTR.
Standard response letter on the use of vutrisiran in patients with wild-type ATTR.
Vutrisiran: Use in Patients with Renal Impairment
Standard response letter on vutrisiran and use in patients with renal impairment.
Standard response letter on vutrisiran and use in patients with renal impairment.
Transition between Patisiran and Vutrisiran
Standard response letter on transitioning between patisiran and vutrisiran therapy.
Standard response letter on transitioning between patisiran and vutrisiran therapy.
Vutrisiran: Post-Orthotopic Liver Transplant
Standard response letter on the exclusion of patients with a history of liver transplant from the HELIOS studies of vutrisiran.
Standard response letter on the exclusion of patients with a history of liver transplant from the HELIOS studies of vutrisiran.
Mivelsiran: cAPPricorn-1 Study
Standard response letter on mivelsiran and the phase 2 cAPPricorn-1 study in patients with sporadic or hereditary CAA.
Standard response letter on mivelsiran and the phase 2 cAPPricorn-1 study in patients with sporadic or hereditary CAA.
Patisiran: Cardiac Results from the APOLLO Study
Standard response letter on patisiran and the exploratory cardiac results in the APOLLO study, a study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.
Standard response letter on patisiran and the exploratory cardiac results in the APOLLO study, a study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.
Givosiran: CYP Enzyme Interactions
Standard response letter on CYP enzyme drug-drug interactions with givosiran.
Standard response letter on CYP enzyme drug-drug interactions with givosiran.
